Melanotan II (MT-2): a real skin-darkening drug with real, unapproved risks

Melanotan II — usually shortened to MT-2 — is unusual among the peptides people inject for cosmetic or recreational reasons, because it actually does the headline thing: it darkens skin. That is not a marketing exaggeration. MT-2 is a synthetic agonist at the melanocortin receptors, and through the melanocortin-1 receptor on pigment cells it drives real melanin production. The problem is everything that comes with it. MT-2 is not an approved medicine anywhere, it is sold as an unregulated powder you reconstitute and inject yourself, and the documented harms run from unpleasant to genuinely dangerous. This is one of the few “research peptides” where the honest verdict is not “interesting but unproven” — it is “it works, and that is part of the problem.”

What melanotan II actually is

MT-2 is a small cyclic peptide analog of α-melanocyte-stimulating hormone (α-MSH), the body’s natural pigment signal. By mimicking α-MSH at melanocortin receptors it stimulates melanocytes to produce more eumelanin, which is why it tans skin with far less ultraviolet exposure than you would otherwise need. Because melanocortin receptors are spread across several tissues, MT-2 also produces off-target effects that became part of its underground appeal: appetite suppression and, via central melanocortin pathways, erections — the same MC4R activity exploited by the approved libido drug bremelanotide. We cover that licensed cousin in our PT-141 (bremelanotide) evidence review; MT-2 is the unlicensed, broader-acting relative.

A peer-reviewed dermatology review of “the risks of unregulated use of α-MSH analogues” lays out the situation plainly: these agents have genuine biological activity, they are bought online and self-injected outside any medical system, and that combination — real pharmacology plus zero oversight — is precisely what makes them hazardous.^[1]

The effect is real — and so is the marketing around it

Most of what MT-2 is sold for clusters around three claims: a deep tan with minimal sun, blunted appetite, and improved erections. The tanning effect is the best characterized and the one with a coherent mechanism. The others ride on the same melanocortin pharmacology but are far less controlled or predictable in the doses people actually use. None of this is delivered by a standardized product. There is no approved formulation, no verified concentration, and no dosing label — so even the “it works” part arrives attached to an unknown quantity of an unknown-purity powder. That is why this monograph deliberately does not provide injection dosing for human use: there is no legitimate protocol to cite, and putting numbers on a screen would imply a safety that does not exist.

The mole problem — the risk that matters most

For a drug whose entire job is to ramp up melanocyte activity, the most important safety signal is what it does to moles. The dermatology literature is unusually concrete here. A BMJ report documented a user whose moles visibly changed after using an unlicensed “sun tan jab,” prompting concern about masked or accelerated melanocytic change.^[2] A separate case described eruptive new naevi and darkening of pre-existing moles appearing within 24 hours of a single MT-2 injection — a strikingly fast melanocytic response.^[3] The clinical worry is twofold: MT-2 can darken existing lesions in ways that confound the visual surveillance dermatologists rely on to catch melanoma early, and it drives new pigmented lesions whose long-term behavior is unknown. The review of α-MSH analogue risks treats these melanocytic changes as a central reason for caution, not a footnote.^[1]

The acute harms: priapism, cardiovascular and neurological events

Beyond pigment, MT-2 has a documented record of acute medical events. Priapism — a prolonged, painful erection that is a urological emergency — has been reported in the setting of MT-2 overdose.^[4] On the vascular side, a published case linked MT-2 use to renal infarction, underscoring that its cardiovascular and blood-pressure effects are not merely theoretical.^[5]And in the neurological column, MT-2 has been associated with posterior reversible encephalopathy syndrome (PRES), a serious condition involving headache, visual disturbance and seizures that is closely tied to acute blood-pressure surges.^[6] Individually these are rare. Collectively they sketch a molecule with real systemic reach — exactly what you would expect from an agonist hitting receptors throughout the body, delivered at uncontrolled doses.

The distinction that gets lost: MT-2 is not afamelanotide

This is the single most important point, and it is constantly blurred online. Melanotan II is not the same thing as afamelanotide — the FDA-approved melanocortin analog sold as Scenesse. Afamelanotide is a different molecule (more closely related to what is loosely called “melanotan 1”), and it is a legitimately approved drug for a specific rare disease: erythropoietic protoporphyria (EPP), a painful light-sensitivity disorder. Its approval rests on a randomized controlled trial published in the New England Journal of Medicine showing it increased pain-free light exposure in EPP patients.^[7] That is a regulated medicine, given as a controlled-release implant under medical supervision for a defined indication.

MT-2 borrows the “melanotan” name and the melanocortin mechanism, but it has none of that standing: no approval, no controlled formulation, no medical indication, and no oversight. Conflating the two — “it’s basically an approved drug” — is one of the most common and most dangerous claims in the MT-2 marketplace. An approved analog for a rare disease does not launder the safety of an unlicensed cousin bought as gray-market powder. For the full side-by-side, see our melanotan 1 vs melanotan 2 comparison.

If you’re sourcing it anyway: the supply problem

Because MT-2 has no legitimate pharmacy route, everything sold is gray-market “research” powder — which adds a second, independent layer of risk on top of the molecule itself: you do not actually know what is in the vial, at what dose, or free of what contaminants. We treat that sourcing problem in detail in where to get peptides safely, and the broader economics in peptide therapy cost. For MT-2 specifically, the “cheap and easy” framing hides both an unverified product and a real harm profile.

The honest bottom line

Melanotan II is not a placebo and not a phantom: it is a real melanocortin agonist that genuinely darkens skin and reaches receptors throughout the body. But it is unapproved, sold as an unregulated injectable powder, and carries a documented harm record — from nausea, flushing and blood-pressure effects to priapism, to the melanocytic changes that undermine melanoma surveillance, to rare but serious events like renal infarction and PRES. Critically, it is not the approved melanocortin drug afamelanotide, and treating it as if it were is the marketplace’s most dangerous sleight of hand. Our grade is straightforward: real effect, real risks, no legitimate approval — one of the genuinely riskier peptides on the gray market. To see how it ranks against better-supported options, browse our peptide evidence matrix and our vetted peptide therapy provider comparison.